Skip to main content
main-content

Breast cancer

News and opinion

02-05-2019 | Radiotherapy | News

Biologic, genetic markers predict radiation toxicity in oncology patients

A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.

23-04-2019 | Oligometastases | News

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

04-04-2019 | TRK inhibitors | AACR 2019 | News

LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors

Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.

02-04-2019 | Advanced breast cancer | Editorial | Article

The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

01-04-2019 | Malignant pleural disease | AACR 2019 | News

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

01-02-2019 | EMA | News

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

13-12-2018 | HER2-positive breast cancer | News

Adjuvant trastuzumab emtansine reduces HER2-positive breast cancer recurrence risk

Among patients with early-stage HER2-positive breast cancer who have residual disease after neoadjuvant therapy and surgery, the use of trastuzumab emtansine instead of trastuzumab leads to significant improvements in invasive disease-free survival, indicate KATHERINE trial findings.

03-12-2018 | FDA | Drug approval | News

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

06-11-2018 | Breast cancer | News

Early risers may have reduced breast cancer risk

Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.

06-11-2018 | Chemoprevention | News

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

05-11-2018 | Breast cancer | ESMO 2018 | News

Epigenetic therapy shows promise for HR-positive advanced breast cancer

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

24-10-2018 | Tamoxifen | ESMO 2018 | Video

Serum analysis sheds light on tamoxifen adherence

Barbara Pistilli discusses the CANTO COMPLETE study of premenopausal breast cancer patient adherence to endocrine therapy (4:31).

24-10-2018 | Breast cancer | ESMO 2018 | Video

Evaluating alpelisib addition to standard of care in SOLAR-1

We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

23-10-2018 | Breast cancer | ESMO 2018 | News

Serum testing reveals tamoxifen therapy nonadherence

Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.

21-10-2018 | Triple-negative breast cancer | ESMO 2018 | News

IMpassion130 supports atezolizumab use in triple-negative breast cancer

Results for the IMpassion130 trial support the combination of atezolizumab and nab-paclitaxel for the treatment of metastatic triple-negative breast cancer, especially among patients with programmed cell death ligand 1-positive disease.

21-10-2018 | Breast cancer | ESMO 2018 | News

Adding alpelisib to fulvestrant boosts PI3KCA-mutant metastatic breast cancer PFS

Patients with hormone receptor-positive, HER2-negative metastatic breast cancer harboring PI3KCA mutations derive a significant progression-free survival benefit when fulvestrant is supplemented with the PI3K inhibitor alpelisib, phase III data show.

20-10-2018 | Breast cancer | ESMO 2018 | News

Further evidence for palbociclib addition in advanced breast cancer

PALOMA-3 trial findings show that overall survival is significantly improved with the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer and sensitivity to prior endocrine therapy.

Image Credits